27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
During a mean follow-up of 3.9 years, dementia was documented in 193 (6.3%) of the 3051 randomized participants in the actively treated group and 217 (7.1%) of the 3054 randomized participants in the placebo group (relative risk reduction, 12% [95% confidence interval, -8% to 28%]; P =.2). 4 key findings →
Participants: 6,105 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The efficacy and safety of donepezil as a treatment for patients with mild to moderate Alzheimer's disease (AD) was investigated in a multicenter, double-blind study. 4 key findings →
Participants: 162 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This clinical trial evaluates the efficacy and safety of a 6-week course of daily neuroAD™ therapy. 4 key findings →
Participants: 131 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Vascular cognitive impairment (VCI) describes a broad spectrum of cognitive impairments caused by cerebrovascular disease, ranging from mild cognitive impairment to dementia. 4 key findings →
Design: meta-analysis Participants: 2,193 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Exogenous low dose melatonin administered nightly to elderly patients admitted to acute care may represent a potential protective agent against delirium. 3 key findings →
Participants: 145 Evidence: high
Full summary, score breakdown and related studies → Original source
These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition. 5 key findings →
Participants: 603 Evidence: high
Full summary, score breakdown and related studies → Original source
Gradual up-titration of dose significantly reduced ARIA-E risk while demonstrating comparable pharmacokinetics/pharmacodynamics compared to standard dosing. 5 key findings →
Design: phase-3-trial Participants: 843 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Synthesis methods We meta-analysed results for each outcome within each comparison using the inverse variance method and the random-effects model. 5 key findings →
Design: meta-analysis Participants: 20,342 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Reduction of amyloid via amyloid-targeting therapies may result in clinical benefit. 2 key findings →
Design: clinical trial Participants: 1,582 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Two hundred eighty-eight patients had paired scans (mean interval 10.9 months). 2 key findings →
Participants: 45 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. 4 key findings →
Design: randomized controlled trial Participants: 640 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
EGb was safe and appears capable of stabilizing and, in a substantial number of cases, improving the cognitive performance and the social functioning of demented patients for 6 months to 1 year. 5 key findings →
Participants: 309 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
p75 neurotrophin receptor (p75 NTR ) signaling pathways substantially overlap with degenerative networks active in Alzheimer disease (AD). 2 key findings →
Participants: 242 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
PDE5I initiation in men with ED was associated with a lower risk of AD, particularly in those most frequently issued prescriptions. 5 key findings →
Design: randomized controlled trial Participants: 269,725 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). 4 key findings →
Participants: 182 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Aerobic exercise in early AD is associated with benefits in functional ability. 4 key findings →
Design: randomized controlled trial Participants: 68 Evidence: high
Full summary, score breakdown and related studies → Original source
The experimental paradigm was feasible and acceptable. 3 key findings →
Design: randomized controlled trial Participants: 95 Evidence: high
Full summary, score breakdown and related studies → Original source
Median follow-up increased from 2.0 years in the double-blind trial to 3.9 years overall. 2 key findings →
Participants: 1,485 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Exercise training for patients with Alzheimer disease combined with teaching caregivers how to manage behavioral problems may help decrease the frailty and behavioral impairment that are often prevalent in patients with Alzheimer disease. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Simvastatin had no benefit on the progression of symptoms in individuals with mild to moderate AD despite significant lowering of cholesterol. 4 key findings →
Participants: 406 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
With the sequential parallel comparison design, 152 patients received dextromethorphan-quinidine and 127 received placebo during the study. 3 key findings →
Design: clinical trial Participants: 93 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Patients taking rivastigmine were significantly less apathetic and anxious, and had fewer delusions and hallucinations while on treatment than controls. 4 key findings →
Participants: 120 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The SYNERGIC Trial will establish the efficacy and feasibility of a multimodal intervention to improve cognitive performance and mobility outcomes in MCI. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Among patients with agitated delirium receiving mechanical ventilation in the intensive care unit, the addition of dexmedetomidine to standard care compared with standard care alone (placebo) resulted in more ventilator-free hours at 7 days. 5 key findings →
Participants: 39 Evidence: high
Full summary, score breakdown and related studies → Original source
This is the primary Phase 3 Clarity AD trial report for lecanemab. 3 key findings →
Design: phase-3-trial Participants: 1,795 Evidence: moderate
Full summary, score breakdown and related studies → Original source
10 of the 795 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →